Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% ...

Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...

Jazz Pharmaceuticals PLC (JAZZ) achieves record-breaking revenue in 2024, outlines strategic growth initiatives for 2025 ...

Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report ...

Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) ...

New York State Common Retirement Fund lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) ...

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd brought ...

Barclays analyst Balaji Prasad raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $190 and keeps an Overweight rating ...

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today. The company’s ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2024 and ...

Highlights,CIBC Asset Management and UMB Bank have boosted their stakes in Jazz Pharmaceuticals.,The company continues to ...